Sarepta Therapeutics Stock Performance
| SRPT Stock | USD 60.44 0.95 1.60% |
The entity has a beta of 1.57, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Sarepta Therapeutics will likely underperform. At this point, Sarepta Therapeutics has a negative expected return of -0.93%. Please make sure to validate Sarepta Therapeutics' maximum drawdown, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if Sarepta Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Sarepta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in May 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 0.3 | Five Day Return 11.4 | Year To Date Return (52.06) | Ten Year Return 335.51 | All Time Return 52.54 |
Last Split Factor 1:6 | Last Split Date 2012-07-12 |
1 | Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3 | 01/28/2025 |
2 | Disposition of 1533 shares by Ian Estepan of Sarepta Therapeutics at 12.0 subject to Rule 16b-3 | 01/29/2025 |
3 | Insider Trading | 02/28/2025 |
4 | Disposition of 17500 shares by Bilal Arif of Sarepta Therapeutics subject to Rule 16b-3 | 03/06/2025 |
5 | Disposition of 296 shares by Rothfuss Cristin of Sarepta Therapeutics at 101.34 subject to Rule 16b-3 | 03/21/2025 |
6 | Sarepta Therapeutics Rating Lowered to Sector Perform at Royal Bank of Canada | 03/31/2025 |
7 | Sarepta and Roche aim to resume paused Elevidys trials following patient death | 04/07/2025 |
8 | Wells Fargo Starts Sarepta with Overweight Rating, Targets 115 SRPT Stock News | 04/11/2025 |
9 | Analysis-Trump health policy uncertainty sends biotech sector into deeper slump | 04/14/2025 |
10 | Summit Investment Advisors Inc. Cuts Stock Position in Sarepta Therapeutics, Inc. | 04/15/2025 |
11 | AIRNA Appoints Jacob Elkins Chief Medical Officer | 04/16/2025 |
12 | Sarepta Therapeutics NASDAQSRPT investor one-year losses grow to 54 percent as the stock sheds US166m this past week | 04/17/2025 |
13 | INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta ... | 04/21/2025 |
14 | Sarepta Therapeutics to Announce First Quarter 2025 Financial Results SRPT Stock News | 04/22/2025 |
| Begin Period Cash Flow | 444 M |
Sarepta Therapeutics Relative Risk vs. Return Landscape
If you would invest 11,646 in Sarepta Therapeutics on January 24, 2025 and sell it today you would lose (5,697) from holding Sarepta Therapeutics or give up 48.92% of portfolio value over 90 days. Sarepta Therapeutics is currently does not generate positive expected returns and assumes 5.2538% risk (volatility on return distribution) over the 90 days horizon. In different words, 46% of stocks are less volatile than Sarepta, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Sarepta Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sarepta Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sarepta Therapeutics, and traders can use it to determine the average amount a Sarepta Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1769
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SRPT |
Estimated Market Risk
| 5.25 actual daily | 46 54% of assets are more volatile |
Expected Return
| -0.93 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Sarepta Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sarepta Therapeutics by adding Sarepta Therapeutics to a well-diversified portfolio.
Sarepta Therapeutics Fundamentals Growth
Sarepta Stock prices reflect investors' perceptions of the future prospects and financial health of Sarepta Therapeutics, and Sarepta Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sarepta Stock performance.
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0377 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 5.74 B | ||||
| Shares Outstanding | 97.03 M | ||||
| Price To Earning | (20.43) X | ||||
| Price To Book | 3.77 X | ||||
| Price To Sales | 3.03 X | ||||
| Revenue | 1.9 B | ||||
| Gross Profit | 778.36 M | ||||
| EBITDA | 316.89 M | ||||
| Net Income | 235.24 M | ||||
| Cash And Equivalents | 2.07 B | ||||
| Cash Per Share | 23.61 X | ||||
| Total Debt | 1.33 B | ||||
| Debt To Equity | 3.72 % | ||||
| Current Ratio | 4.36 X | ||||
| Book Value Per Share | 15.77 X | ||||
| Cash Flow From Operations | (205.79 M) | ||||
| Earnings Per Share | 2.34 X | ||||
| Market Capitalization | 5.75 B | ||||
| Total Asset | 3.96 B | ||||
| Retained Earnings | (4.21 B) | ||||
| Working Capital | 2.34 B | ||||
| Current Asset | 434.74 M | ||||
| Current Liabilities | 64.93 M | ||||
About Sarepta Therapeutics Performance
Assessing Sarepta Therapeutics' fundamental ratios provides investors with valuable insights into Sarepta Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Sarepta Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 857.84 | 814.95 | |
| Return On Tangible Assets | 0.06 | 0.06 | |
| Return On Capital Employed | 0.07 | 0.07 | |
| Return On Assets | 0.06 | 0.06 | |
| Return On Equity | 0.15 | 0.16 |
Things to note about Sarepta Therapeutics performance evaluation
Checking the ongoing alerts about Sarepta Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sarepta Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sarepta Therapeutics generated a negative expected return over the last 90 days | |
| Sarepta Therapeutics has high historical volatility and very poor performance | |
| Sarepta Therapeutics is unlikely to experience financial distress in the next 2 years | |
| Sarepta Therapeutics currently holds about 2.07 B in cash with (205.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.61. | |
| Sarepta Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Sarepta Therapeutics to Announce First Quarter 2025 Financial Results SRPT Stock News |
- Analyzing Sarepta Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sarepta Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Sarepta Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sarepta Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sarepta Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sarepta Therapeutics' stock. These opinions can provide insight into Sarepta Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Sarepta Stock Analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.